Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report April - June 2021

Gothenburg, August 26, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2021.Important events during the second quarter · In May, Vicore[1] announced that it had entered into a collaboration agreement with Alex Therapeutics for the development of a digital therapeutic (DTx) for patients living with idiopathic pulmonary fibrosis (IPF). · In June, Vicore announced that it had received approval from the U.S. Food and Drug Administration (FDA) to start the pivotal phase 3 trial with C21 in COVID-19. Important events after the period · No

Half-Year Financials, January 1 – June 30 2021

Faron Pharmaceuticals Oy (“Faron”) Faron Reports Half-Year Financials, January 1 – June 30, 2021 Significant progress made in H1 2021 including acceleration of most advanced pipeline assets - Bexmarilimab and Traumakine[Ò] August 26, 2021 at 7:00 am BST / 9:00 am EEST January – June 2021 in short/ Summary of January – June 2021 · Bexmarilimab shows compelling antitumor activity in multiple advanced solid tumor types as a monotherapy with strongest disease control rate, DCR (30.0% - 40.0%), observed in cutaneous melanoma, gastric cancer, cholangiocarcinoma and

BioInvent International AB: Interim report January-June 2021

“We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial program with our anti-TNFR2 antibody BI-1808. We are excited about the potential synergistic activity of BI-1808 in combination with pembrolizumab and this agreement supports the strong interest elicited by our broadening pipeline of anti-cancer antibodies.”- CEO Martin Welschof on the new agreement with Merck. Events in the quarter • BioInvent received IND approval for Phase 1/2a trial of anti-TNFR2 antibody BI-1808. • BioInvent and Transgene

SAGAX COMPLETES TAP ISSUE OF BOND LOAN 2021/2029

AB Sagax (publ) has, as under its EMTN programme, issued senior unsecured bonds of EUR 200 million with maturity in 2029. The issue is part of bond loan 2021/2029 (ISIN XS2342227837) with an aggregate amount of EUR 500 million after the tap issue. The bonds were issued at a price of 101.024 per cent which corresponds to a fixed annual yield of 0.86 per cent. The proceeds will be used for the company’s operating activities. For further information, please contact CEO David Mindus, telephone +46 8 545 83 540. About Sagax AB Sagax is a property company whose business concept is

Quickbit partners with Bank Frick for acquiring services

Quickbit has entered into an agreement with Bank Frick and adds another acquiring partner for card-to-crypto transactions. Bank Frick is an enterprising bank specialising in cutting-edge blockchain banking services. Adding Bank Frick as an acquiring partner supports Quickbits growth ambitions and lowers over time Quickbits transaction and introducer costs.The agreement offers Quickbit attractive terms and helps Quickbit lower its transaction and introducer costs over time. Bank Frick is an enterprising bank which offers a range of services designed for financial intermediaries and

Net Trading Group Interim Report Q2 2021

Net Trading Group NTG AB (publ) Interim report 1 January–30 June 2021The Board of Directors and the CEO of Net Trading Group NTG AB (publ) hereby submit the interim report for the first half of 2021. Summary of Group for the May–June 2021 period ·  Net sales amounted to kSEK 83 (–) ·  Operating loss amounted to kSEK -6,244 (–) ·  Diluted earnings per share SEK -0.01 (–) ·  Cash and cash equivalents at period end amounted to kSEK 4,694 (–) Summary of Parent Company for the April–June 2021 period · Net sales amounted to kSEK 0 (-55) · Operating loss amounted

IRRAS AB publishes Interim Report for the period, January to June 2021

Commercial Growth Continues“Q2 2021 marks the fourth consecutive quarter of growth for IRRAS despite the challenges of the COVID-19 pandemic, and the company is positioned to continue this positive growth trajectory." “This is an exciting time for IRRAS as our forward progress accelerates. A record number of patients were treated with our products during Q2, and published clinical data and surgeon feedback both support our company’s positive impact on critically ill patients.” Will Martin, President and CEO of IRRAS Second Quarter, April – June 2021, Results · Net revenue

Polygiene AB (publ.) Interim Report 1 April – 30 June, 2021

Another strong quarter with profitable growth paves the way forwardQ2 in brief (April - June 2021) · Net sales amounted to MSEK 46.9 during the second quarter and had a positive growth by171 % compared to the same period last year · The operating profit/loss EBIT amounted to MSEK 10.0 (-1.1) · The gross margin amounted to 61.8 (70.3) % · The cash flow is improved compared to the same quarter last year, MSEK 5.2 (0.0)  Events during the quarter (April - June 2021) · Nine West and Polygiene® Lounge Wear apparel sold out in successful Korean Hyundai Home Shopping

Clavister Q2 2021: Order Intake Growth of 55%

August 26, 2021, Örnsköldsvik, Sweden. Clavister, a leader in high-performance cybersecurity solutions, released its latest quarterly report for 2021. “Our second quarter of 2021 saw positive development of several metrics, especially order intake, recurring revenue and operational cash flow. We have good momentum in the Service Provider space as we execute on our refined strategic direction.” John Vestberg,President and CEO The Second Quarter · Order Intake amounted to 84.7 (54.8) MSEK · Net Sales amounted to 29.6 (28.5) MSEK. FX adjusted Net Sales amounted to 30.0 (28.5),

Karnov Group reports second quarter results 2021

Continued expansionFINANCIAL HIGHLIGHTS SECOND QUARTER · Net sales increased to SEK 201 m (178), organic growth was 7%. · EBITA amounted to SEK 70 m (63) with EBITA margin of 35.0% (35.5%). · Adjusted EBITA amounted to SEK 70 m (63) with adjusted EBITA margin of 35.0% (35.5%). · Net result amounted to SEK 20 m (27). · Earnings per share after dilution amounted to SEK 0.20 (0.27). · Adjusted operating cash flow amounted to SEK 38 m (49). CEO Pontus bodelsson comments on the quarter: Having joined Karnov Group and assumed my position as President and CEO in May 2021,

Metacon AB (publ) quarterly report Q2 2021

PARENT COMPANY APRIL 1 – JUNE 30, 2021 · Total revenues amounted to 0 (0) kSEK · Operating result amounted to -3 136 (-2 154) kSEK · Result after financial items amounted to -3 188 (-2 214) kSEK CONSOLIDATED GROUP APRIL 1 – JUNE 30, 2021 · Total revenues amounted to 38 (1 128) kSEK · Operating result amounted to -7 992 (-3 284) kSEK · Result after financial items amounted to -8 085 (-3 193) kSEK · Earnings per share amounted to -0,03 SEK SIGNIFICANT EVENTS DURING THE PERIOD APRIL 1 – JUNE 30, 2021 · Metacon had its Annual General Meeting on June 8. Due to

Interim Results

26 August 2021 1H 2021 Interim Results IOG plc ("IOG" or the "Company" or "Group") (AIM: IOG.L), the Net Zero UK gas and infrastructure operator focused on high return projects, is pleased to present its unaudited interim results for the six months ended 30 June 2021. Corporate and Operational Highlights · Core Project and associated Thames infrastructure renamed as the Saturn Banks Project and Saturn Banks Pipeline System ("SBPS"), a reference to local seabed features in the Southern North Sea ("SNS") · Fabrication, transportation and installation of both the Saturn Banks

Herantis Pharma: Results for the First Half Year January 1 – June 30, 2021

Herantis Pharma Plc Company Release August 26, 2021, at 9:00 a.m. EEST/8:00 a.m. CEST Dr. Craig Cook CEO of Herantis commented: “In 2021, Herantis continued to optimize its assets and shape the company for future success as we transformed into a pure play CNS biotech company. The continued generation of strong data prompted our strategic decision to focus on our CNS assets, CDNF and xCDNF (HER-096). Following more than a decade of extensive R&D for CDNF and xCDNF, we are now reaping the fruits of those efforts.” Herantis Pharma Plc (“Herantis”), focusing on disease modifying

Arctic Bioscience H1 2021 results: phase IIb study on track and revenue up 50% y/y

Arctic Bioscience AS (“Arctic Bioscience” or “the company”) today announces its results for the first half 2021.   Highlights · Successful private placement and IPO raising NOK 300 million, with first day of trading on Euronext Growth on 24 February 2021 · On track and on budget for phase IIb clinical study on HRO350 in mild-to-moderate psoriasis, planned start H1 2022 · Financial strength to execute on ongoing development programs, invest in new production facility and capacity to participate in new selected pre-clinical trials · Revenue increased 50% y/y driven by

Elekta’s Board announces establishment of philanthropic Elekta Foundation

Shareholders agree to support initiatives that expand access to cancer careSTOCKHOLM, August 26, 2021 – At its Annual General Meeting on August 25, Elekta’s (EKTA-B.ST) shareholders approved the Board of Directors’ proposal to establish the Elekta Foundation. The Elekta Foundation’s mission is an important part of Elekta’s environmental, social, and governance (ESG) strategy and priorities. Its mission is to initiate and support projects and programs in partnership with governments, NGOs and healthcare providers in low- and middle-income countries to improve access to cancer care. Dr.

Hunter Group ASA - Second quarter results 2021

Oslo, 26 August 2021   Financial highlights Total revenues of USD 11.50m - Spot pool revenues of USD 1.50m - Time charter revenues of USD 7.23m Total operating expenses of USD 6.6m - Vessel opex incl. insurance of USD 2.50m - Voyage exp. and commissions of USD 0.43m G&A expenses of 0.38m - USD 0.37m administrative expenses - USD 0.01m legal expenses EBITDA of USD 8.18m Net profit of USD 2.38m   Average daily earnings of USD 24,000 - Avg. daily spot earnings of USD 15,500 - Avg. daily time charter earnings of USD 26,500  Opex incl.

Metsä Fibre and Lehto sign an agreement to build an ecological operating office for the Kemi bioproduct mill

Metsä Fibre press release 26.8.2021Metsä Fibre, part of Metsä Group, and the construction company Lehto Group have entered into an agreement to build an ecological operating office from wood for the Kemi bioproduct mill in Finland. The operating office will have a high degree of Finnish origin, approximately 80%, Finnish wood and high-quality products made from it will play a major role in the construction project. Kerto® LVL wood products from Metsä Wood, part of Metsä Group, will be used in construction. They are made from Finnish wood in Finland. The future office building will be an

RugVista Group (publ) interim report January – June 2021

Continued growth in-line with long-term financial targetSecond quarter 2021 highlights · Net revenue was SEK 140.6 (124.3) million representing a growth of 13.2% (47.8%). · Net revenue growth excluding divested operations was 18.4% (48.1%). · Organic net revenue growth was 22.6%. · Gross margin increased to 64.1% (62.2%). · EBIT grew to SEK 24.8 (23.0) million and EBIT margin was 17.6% (18.5%). · Profit for the period was SEK 18.6 (17.5) million. · Earnings per share was SEK 0.89 (0.87). · Net Promotor Score (NPS) value was 66 (-). January – June 2021 highlights

AQUAPORIN ANNOUNCES RESULTS FOR FIRST HALF 2021

The full interim report is attached to this announcement. Highlights · Successful capital raise of DKK 250 million in gross proceeds in connection with initial public offering secured funds to execute on the commercialization strategy laid out in the Prospectus published 14 June 2021. · Revenue grew 176% to DKK 2.9 million in the first six months of 2021 (1.0 million); Drinking Water (60%) and Industrial Water (37%) were the primary revenue drivers. · Drinking water revenue growth was driven by sales in both point-of-use (“PoU”) systems (purifiers, systems) and non-PoU (

NRC Group ASA – Crown Bridges tramway approval

The Helsinki City Council approved the construction phase of the Crown Bridges tramway and the cost estimate for the project. The revised cost estimate is around EUR 326 million, with NRC Group Finland’s (“NRC Group”) share amounting to approximately EUR 100-110 million. The contract includes construction of the tramway and other street construction projects to develop the city. This includes the construction of a new Hakaniemi bridge to replace a dilapidated bridge and the construction of new Hakaniemi streets. According to the preliminary project schedule, track construction is

Interim report, January - June 2021

In Q2 2021 net sales increased by 36.7% compared to Q2 2020. Consolidated net sales ended at 53,397 (SEK 000s). EBITDA totaled to -4,570 (SEK 000s). Operating profit, EBIT, was -19,306 (SEK 000s). Profit after tax was -43,025 (SEK 000s). Earnings per share was SEK -0.64. For 1H 2021 net sales increased by 25.8% compared to 1H 2020. Consolidated net sales ended at 101,919 (SEK 000s). EBITDA totaled to -3,733 (SEK 000s). Operating profit, EBIT, was -21,760 (SEK 000s). Profit after tax was -41,796 (SEK 000s). Earnings per share was SEK -0.62.CEO's comments The 24SevenOffice team

Nanoform Interim Report January – June 2021

Company Announcement Nanoform Finland Plc August 26, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – June 2021 The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross margin forcefully breaks through 90 per cent. Letter of intent signed for the development, manufacturing, and commercialization of a by nanoforming improved version of a current blockbuster drug. Q2/2021 key financials: - Revenue came in at EUR 0.55 million, up 185% compared with EUR 0.

More efficient electricity distribution thanks to new insulation material

High-voltage direct current cables which can efficiently transport electricity over long distances play a vital role in our electricity supply. Optimising their performance is therefore an important challenge. With that aim in mind, scientists from Chalmers University of Technology, Sweden, present a new insulation material up to three times less conductive, offering significant improvements to the properties and performance of such cables.If we are to transition to a world powered by renewable energy, efficient long-distance transport of electricity is essential, since the supply –

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during sixth exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or “the company”) today announces that the sixth period to subscribe for shares in the company by exercise of warrants (ticker CTM TO1) (“the warrants”) commences today, 26 August 2021, and will run until and including 4 September 2021. During this period, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 18.90. Payment of subscribed shares can be made in cash or through set-off with the full nominal amount of each hybrid capital security (ticker

There are no items matching the current filter
There are no more items matching the current filter
Back to top